Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732807 · ClinicalTrials.gov registry record · Phase 2
PF-06651600 for the Treatment of Alopecia Areata
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 718
- Enrollment target
NCT03732807: Completed Phase 2 study, sponsored by Pfizer.
NCT03732807 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 718 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (440% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03732807, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 718 participants
- Enrollment target
Study Summary
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Primary Outcome
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.
Interventions
- DRUG Placebo
- DRUG PF-06651600 Induction Dose
- DRUG PF-06651600 Maintenance Dose #1
- DRUG PF-06651600 Maintenance Dose #2
- DRUG PF-06651600 Maintenance Dose #3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 2 |
What the finished NCT03732807 record still lists
NCT03732807 is an interventional study that assigns participants to a tested intervention. The registered 718 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (440% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03732807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03732807 about?
NCT03732807 is a clinical study titled "PF-06651600 for the Treatment of Alopecia Areata". This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will...
What is the current status of trial NCT03732807?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 718 participants. The study started on 2018-12-03. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT03732807?
The interventions under investigation include: Placebo (DRUG), PF-06651600 Induction Dose (DRUG), PF-06651600 Maintenance Dose #1 (DRUG), PF-06651600 Maintenance Dose #2 (DRUG), PF-06651600 Maintenance Dose #3 (DRUG).
Who is sponsoring clinical trial NCT03732807?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03732807's enrollment target sits among peer trials
718 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI